Post by seanismorris on Apr 13, 2014 5:51:19 GMT -5
Medicon Valley Inhalation Consortium (Oct. 16, 2013)
www.mvic.se/wp-content/uploads/2013/09/Proceedings-sessions-1-4-20131.pdf
There are some very nice pictures of the inhalers and useful background info.
I found the comparisons between Afrezza and the others (Eli Lilly, Novo Nordisk) in the charts useful. I had a miner concern when I found (years ago) that the two other companies had abandoned their efforts to bring an inhaled insulin to market. But, the obvious superiority of Afrezza from the chart (ultra fast acting aspect) and now their decision makes sense. Their inhaled products had no clear advantage...
The COPD, asthma and smokers charts..also interesting, especially the smokers because other countries (outside of USA) have a much high % population that smokes.
www.mvic.se/wp-content/uploads/2013/09/Proceedings-sessions-1-4-20131.pdf
There are some very nice pictures of the inhalers and useful background info.
I found the comparisons between Afrezza and the others (Eli Lilly, Novo Nordisk) in the charts useful. I had a miner concern when I found (years ago) that the two other companies had abandoned their efforts to bring an inhaled insulin to market. But, the obvious superiority of Afrezza from the chart (ultra fast acting aspect) and now their decision makes sense. Their inhaled products had no clear advantage...
The COPD, asthma and smokers charts..also interesting, especially the smokers because other countries (outside of USA) have a much high % population that smokes.